Journal article

Insights into the structure of NLR family member X1: Paving the way for innovative drug discovery

S Jewell, TB Nguyen, DB Ascher, AAB Robertson

Computational and Structural Biotechnology Journal | ELSEVIER | Published : 2024

Abstract

Nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1) is a negative regulator of the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) pathway, with a significant role in the context of inflammation. Altered expression of NLRX1 is prevalent in inflammatory diseases leading to interest in NLRX1 as a drug target. There is a lack of structural information available for NLRX1 as only the leucine-rich repeat domain of NLRX1 has been crystallised. This lack of structural data limits progress in understanding function and potential druggability of NLRX1. We have modelled full-length NLRX1 by combining experimental, homology modelled and AlphaFold2 ..

View full abstract

University of Melbourne Researchers

Grants

Awarded by University of Queensland


Funding Acknowledgements

SJ is supported by a University of Queensland Research Training PhD scholarship funded by The University of Queensland. TBN and DBA were supported by the Investigator Grant from the National Health and Medical Research Council (NHMRC) of Australia (GNT1174405 to DBA). Supported in part by the Victorian Government's Operational Infrastructure Support Program.